RORC and neoplasm: By inhibiting Treg development, lowering CD73 and CD39 expression, and lowering expression of coinhibitory receptors such as TIGIT and PD-1 on tumor-reactive cells, RORγ agonists also lessen immunosuppressive mechanisms [205].